Welcome to the latest edition of BioLines Weekender, featuring the latest news on New Jersey’s innovative biopharma community.
Congrats to BioNJ Board Member Anthony Marucci and Celldex Therapeutics on the announcement of the intended acquisition of Kolltan Pharmaceuticals. Anthony and Celldex are 2005 spinouts of the former Medarex which was later acquired by Bristol-Myers Squibb.
This week, the Biotechnology Innovation Organization (BIO) unveiled a highly informative educational video, entitled Understanding Your Drug Costs: Follow the Pill, which provides much needed insight as to how prescription drug costs are determined. We invite you to have a look and to share it with your community.
Because Patients Can’t WaitSM, it is imperative for Patients to be part of the drug development process and play a role in defining the value of medical innovation. BioNJ is pleased to offer a first-ever Beyond Value Frameworks: Defining the Value of Medical Innovation workshop on December 8 at Amicus Therapeutics, Cranbury, NJ. Designed for individuals responsible for pricing, policy, market access and reimbursement, attendees will learn how to get ahead of framework decisions, develop partnerships to challenge value assessments, discuss ways to measure patient-centered value and learn about new analytic computational platforms that can demonstrate and calculate drug value. Click here to register.
Back by popular demand, “Breakfast with BioNJ” is returning on December 13. Save the date and plan to join us for breakfast, networking and a Fireside Chat with Scott Jackson, immediate past CEO of Celator recently acquired by Jazz Pharmaceuticals and Jeff Hatfield past CEO of Vitae Pharma being acquired by Allergan.